The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Sangamo Therapeutics Inc (NASDAQ: SGMO) was $0.38 for the day, down -4.79% from the previous closing price of $0.4. In other words, the price has decreased by -$4.79 from its previous closing price. On the day, 3.89 million shares were traded. SGMO stock price reached its highest trading level at $0.4055 during the session, while it also had its lowest trading level at $0.378.
Ratios:
Our analysis of SGMO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.88 and its Current Ratio is at 0.88. In the meantime, Its Debt-to-Equity ratio is 4.07 whereas as Long-Term Debt/Eq ratio is at 4.07.
On December 13, 2024, Truist Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $7.
H.C. Wainwright reiterated its Buy rating for the stock on December 10, 2024, and also maintained the target price at $10.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGMO now has a Market Capitalization of 127666016 and an Enterprise Value of 123474008. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.88 while its Price-to-Book (P/B) ratio in mrq is 19.57. Its current Enterprise Value per Revenue stands at 3.756 whereas that against EBITDA is -1.18.
Stock Price History:
The Beta on a monthly basis for SGMO is 1.28, which has changed by -0.6637168 over the last 52 weeks, in comparison to a change of 0.15024745 over the same period for the S&P500. Over the past 52 weeks, SGMO has reached a high of $1.40, while it has fallen to a 52-week low of $0.37. The 50-Day Moving Average of the stock is -13.85%, while the 200-Day Moving Average is calculated to be -30.00%.
Shares Statistics:
SGMO traded an average of 5.99M shares per day over the past three months and 4342990 shares per day over the past ten days. A total of 336.49M shares are outstanding, with a floating share count of 329.09M. Insiders hold about 2.20% of the company’s shares, while institutions hold 18.64% stake in the company. Shares short for SGMO as of 1767139200 were 21156433 with a Short Ratio of 3.53, compared to 1764288000 on 17420411. Therefore, it implies a Short% of Shares Outstanding of 21156433 and a Short% of Float of 6.34.
Earnings Estimates
The market rating for Sangamo Therapeutics Inc (SGMO) is a result of the insights provided by 2.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.04 and low estimates of -$0.04.
Analysts are recommending an EPS of between -$0.4 and -$0.42 for the fiscal current year, implying an average EPS of -$0.41. EPS for the following year is -$0.23, with 2.0 analysts recommending between -$0.12 and -$0.34.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 4 analysts. It ranges from a high estimate of $100M to a low estimate of $10M. The current estimate, Sangamo Therapeutics Inc’s year-ago sales were $7.55MFor the next quarter, 4 analysts are estimating revenue of $20.55M. There is a high estimate of $24.8M for the next quarter, whereas the lowest estimate is $16.3M.
A total of 4 analysts have provided revenue estimates for SGMO’s current fiscal year. The highest revenue estimate was $125.3M, while the lowest revenue estimate was $35.3M, resulting in an average revenue estimate of $65.55M. In the same quarter a year ago, actual revenue was $57.8MBased on 4 analysts’ estimates, the company’s revenue will be $55.38M in the next fiscal year. The high estimate is $114.2M and the low estimate is $8.6M.
